Cathay Biotech, Inc.

Cathay Biotech, Inc. has experienced a stock price increase today, reaching an intraday high of CNY 46.88. Despite a total return of 10.93% over the past year, the company faces challenges, including a declining operating profit and concerns about long-term growth, while maintaining a market capitalization of CNY 25,663 million.

Cathay Biotech, Inc. has faced significant stock price declines, with a 4.03% drop today and a 7.89% decrease over the past week. The company struggles with management efficiency, reflected in a low Return on Capital Employed, while long-term growth prospects remain uncertain despite recent positive sales results.

Cathay Biotech, Inc. saw its stock price rise today, contrasting with the broader market. Despite recent modest gains, the company has faced longer-term declines. Positive quarterly results highlight improved operational efficiency, with a notable reduction in raw material costs. Cathay Biotech maintains a significant market capitalization and dividend yield.

Cathay Biotech, Inc. faced a notable decline in its stock price, reaching an intraday low amid a challenging trading session. The company has experienced losses over the past week and month, with its year-to-date performance also reflecting a downturn. Despite some positive indicators, long-term growth metrics remain a concern.

Cathay Biotech, Inc. saw its stock price decline significantly today, reaching an intraday low amid a challenging trading environment. Over the past week and month, the company has also experienced declines, although it has reported positive results for the last four quarters, indicating some operational resilience.

Cathay Biotech, Inc. faced a decline in stock performance on March 18, 2026, contrasting with a slight increase in the China Shanghai Composite. Despite recent challenges and longer-term performance drops, the company reported positive quarterly results, including a return on capital employed of 8.99% and reduced raw material costs.

Cathay Biotech, Inc. saw a decline in stock performance on March 17, 2026, contrasting with the broader market. Over the past year, the company has underperformed compared to the China Shanghai Composite, despite reporting positive results for four consecutive quarters and a reduction in raw material costs.

Cathay Biotech, Inc. has seen a significant rise in stock performance, gaining 3.91% today and 7.31% over the past week. Despite challenges in long-term growth metrics, the company has reported consistent quarterly results and reduced raw material costs, maintaining a strong position in the specialty chemicals industry.

Cathay Biotech, Inc. has experienced notable stock activity, reaching an intraday high amid a declining market. While the company has shown positive quarterly results, its longer-term performance is mixed, with low return on capital employed and a decline in operating profit over five years, despite modest net sales growth.

Cathay Biotech, Inc. faced a decline on March 5, 2026, amid broader market pressures. The company has seen a decrease over the past week and month, despite a modest year-to-date performance. Challenges include low ROCE and ROE, with a cautious outlook reflected in its valuation metrics.

Cathay Biotech, Inc. has shown strong performance in the specialty chemicals sector, with a notable increase on October 27, 2025. The company reported a 35.4% rise in profits over the past year and maintains a solid cash position, reflecting its robust market standing despite recent fluctuations.

Cathay Biotech, Inc. faced a decline in stock value on October 14, 2025, amid a challenging trading environment. Despite recent fluctuations, the company has reported positive quarterly results and maintains a strong cash position. Its valuation metrics indicate operational stability, although long-term performance has been mixed.